TD has acquired Cowen Inc. Please bookmark TD Securities for further updates.

$105 Million

TransMedics Group, Inc

Initial Public Offering

Co-Manager, May 2019

TransMedics Group, Inc
TransMedics is a commercial-stage medical technology company transforming organ transplant therapy for end-stage organ failure patients across multiple disease states. TransMedics developed the Organ Care System, or the OCS, to replace a decades-old standard of care that the Company believes is significantly limiting access to life-saving transplant therapy for hundreds of thousands of patients worldwide. The innovative OCS technology replicates many aspects of the organ's natural living and functioning environment outside of the human body. As such, the OCS represents a paradigm shift that transforms organ preservation for transplantation from a static state to a dynamic environment that enables new capabilities, including organ optimization and assessment. TransMedics believes its substantial body of clinical evidence has demonstrated the potential for the OCS to significantly increase the number of organ transplants and improve post-transplant outcomes